Merus NV Stock Quote MRUS - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

54.19

Bid

52.26

Ask

57.12

Volume

263,758

53.70 Day's Range 55.69

19.805 52 Week Range 61.61

Market Cap

3.18B

Previous Close

54.32

Open

54.79

Last Trade

776

54.19

(priorref)

Last Trade Time

Financial Volume

$ 14,351,698

VWAP

54.4124

Average Volume (3m)

1,059,690

Shares Outstanding

58,687,551

Dividend Yield

PE Ratio

Earnings Per Share (EPS)

Revenue

Net Profit

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector

Gen Med & Surgical Hospitals

Industry

Gen Med & Surgical Hospitals

Website

www.merus.nl

Headquarters

Utrecht, Utrecht, Nld

Founded

1970

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $54.32. Over the last year, Merus NV shares have traded in a share price range of $ 19.805 to $ 61.61.

Merus NV currently has 58,687,551 shares outstanding. The market capitalization of Merus NV is $3.19 billion.

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.11	-2.00723327306	55.3	56.62	53	403880	55.09468878	CS
4	-5.76	-9.60800667223	59.95	61.28	50.51	789104	56.05813839	CS
12	5.69	11.7319587629	48.5	61.61	42.6	1059690	54.06116739	CS
26	19.97	58.357685564	34.22	61.61	33.725	818272	49.95848443	CS
52	28.01	106.990068755	26.18	61.61	19.805	602362	41.87624775	CS
156	36.01	198.074807481	18.18	61.61	12.03	414913	31.94109954	CS
260	38.39	242.974683544	15.8	61.61	10.18	297518	29.61545563	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	259.77k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M